The Medical Letter on Drugs and Therapeutics
Belimumab (Benlysta) for Systemic Lupus Erythematosus
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Belimumab (Benlysta – Human Genome Sciences/GlaxoSmithKline) has been approved by the FDA for treatment of adults with active, autoantibody-positive, systemic lupus erythematosus (SLE). It is the first biologic agent approved for SLE and the first drug of any kind to be approved for this disease in >50 years.

PHARMACOLOGY — Belimumab is a human IgG1λ monoclonal antibody that blocks the binding of soluble B-lymphocyte stimulator (BLyS, also known as B cell activating factor) to its receptors on B cells. BLyS levels are elevated in SLE and correlate with disease activity.1-3

CLINICAL STUDIES — In two clinical trials, BLISS-52 (52-week follow-up) and BLISS-76 (76-week follow-up), a total of 1684 patients with active SLE were randomized to receive, in addition to their current therapy, belimumab 1 mg/kg, 10 mg/kg or placebo IV at 0, 2 and 4 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Belimumab (Benlysta) for Systemic Lupus Erythematosus
Article code: 1366a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian